natalizumab

natalizumab (TYSABRI) is an FDA-listed pharmaceutical active ingredient. Associated with Biogen. Route of administration: single-use. Current US regulatory status: approved.

TYSABRI is a marketed brand name for natalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

natalizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.